About PanTera

About Pantera

PanTera wants to bring new hope to cancer patients by enabling the widespread application of radiopharmaceuticals for precision treatment of tumors.

Our core belief is that these powerful medical tools deserve a central role in oncology for their potential to treat cancers effectively while preserving patient's quality of life. Our focus is on the radiotheranostics field, which facilitates patient-tailored optimization of treatment by tracking the distribution of therapeutic agents in the body. This cutting-edge approach minimizes patient side-effects while enhancing treatment efficacy.

Our vision is to make such personalized nuclear medicine treatments a reality, making them widely available and affordable. To realize this vision, we are establishing a state-of-the-art production facility for actinium-225 (Ac-225) in Mol, Belgium. Our unique production process, employing the photonuclear or ‘gamma’ route, transforms Radium-226 (²²⁶Ra) into ²²⁵Ra, which in turn decays into Ac-225. This high-purity Ac-225 is then supplied as an Active Product Ingredient (API) to the global pharmaceutical market.

In addition to ensuring quality, we prioritize sustainability. The radium in our process is recycled and reused, emphasizing our commitment to environmentally friendly practices. At PanTera, we are not only supporting the development of the next generation of cancer treatments but also fostering a future where personalized nuclear medicine is the norm.

Leadership

Sven van den bergheCEO
"During my 25 years in nuclear materials and fuels research and development at the Belgian Nuclear Research Centre (SCK CEN), I’ve always felt most proud of the role SCK CEN and its BR2 reactor play in the global supply of medical radioisotopes. Around the time Pantera was created, I lost a dear friend to pancreatic cancer. That was an additional strong motivation to take up the challenge of leading this new company. I didn’t hesitate to leave my position as director of the Nuclear Materials Science Institute at SCK CEN, because the idea that the products we will create will signify new hope for cancer patients around the world, is a powerful driver"

Sven van den berghe
CEO
Christophe MaliceCBO
"Over my career, I have always been driven by turning ambitious visions into reality and make meaningful initiatives happen. Relaying on experiences in Supply-Chain, Product management, Strategy, Business development and Cross functional team leadership, I am thrilled to bring my entrepreneurship mindset and determination at the service of PanTera to make promising therapeutics isotopes accessible over the world. We all have been directly or in-directly confronted to cancer. When a cancer treatment as promising as actinium-225 is about to come, we can only contribute, with the industry, to make it available on the market. This is exactly how we will bring new hope in the fight against cancer.”

Christophe Malice
CBO
Samy BertrandCTO
"Nuclear medicine was already a captivating field when it was almost all about diagnosis. Over the past years, witnessing its incredible shift towards therapeutic and how the power of internal radiation can be used as a cure brought it to another level.

The promising results in improvement the quality of life of cancer patient, combined with the technical challenges to make therapeutic radioisotope available are great sources of motivation for our team.

With 10 years of experience in the field of production of medical radioisotopes, it is a privilege for me to create synergies across our founding partners SCK CEN and IBA, and to make this project a success that will benefit to thousands of cancer patients."

Samy Bertrand
CTO
Yves SterckxDirector of Finance & Administration
"PanTera's dedication to making Actinium-225 widely available to cancer patients worldwide, offering them a better chance in their fight for life makes me very proud to be part of it's Leadership Team. It is extremely motivating to work on a product that will improve the quality of life for so many people.

I am excited to leverage my extensive expertise in Finance, HR, and IT, both in Belgium and abroad, to support PanTera's growth and success by building a robust organization characterized by transparency, full accountability, and the highest standards of integrity.”

Yves Sterckx
Director of Finance & Administration
Philippe VanwolleghemDirector Quality, Regulatory Affairs & HSE
Driven by a deep interest in nuclear medicine and drug vectorization, I have long been inspired by their transformative potential in oncology — particularly in the development of targeted therapies that can selectively eliminate cancer cells while sparing healthy tissue. What motivates me most is the opportunity to not only improve therapeutic efficacy but also enhance patients’ quality of life.

This passion led me to pursue a career in the radiopharmaceutical industry, where I’ve built comprehensive expertise spanning the full lifecycle of radiopharmaceutical products—from early-stage research and development to regulatory approval and commercialization. At PanTera, I am responsible for leading Quality, Regulatory Affairs, and Environment, Health, and Safety (EHS), ensuring that our innovations are developed, manufactured, and delivered to the highest standards of safety, compliance, and operational excellence.

I am particularly focused on advancing the large-scale production of actinium-225 to unlock the full potential of targeted alpha therapy in cancer treatment. With a strong foundation in radiopharmaceutical development and regulatory strategy, I am committed to translating this breakthrough into real-world clinical impact, safely and efficiently delivering innovation to the patients who need it most.

Philippe Vanwolleghem
Director Quality, Regulatory Affairs & HSE

FOUNDERS

PanTera is a joint venture between IBA and SCK CEN

IBA is a world leader in particle accelerator technology. The company designs, produces and markets innovative solutions for the diagnosis and treatment of cancer and other serious illnesses, and for industrial applications such as the sterilization of medical devices.

Around the world, thousands of hospitals use particle accelerators and dosimetry equipment designed, produced, maintained and upgraded by IBA, in our mission to protect, enhance and save lives. Our life-driven mission and the open relationships we have built with our customers and partners over time, together with our innovative mindset and our willingness to always strive for technological and scientific progress, make IBA a unique scientific company. We are characterized by a deep human connection that is illustrated by: Life, Science.

Through our four core activities: Industrial Solutions, RadioPharma Solutions, Proton Therapy and Dosimetry, we offer health care professionals the solutions that allow them to take a fully integrated approach to their patient care.

For more information, please visit www.iba-worldwide.com

With 70 years of experience in nuclear research and technology, SCK CEN is one of the largest research institutions in Belgium. Every day, more than 900 employees dedicate themselves to developing peaceful applications of radioactivity. SCK CEN's research activities focus on three main areas: innovative nuclear systems, nuclear waste management and dismantling, and the resolute fight against cancer. World-renowned, SCK CEN shares its knowledge through countless publications and training courses, so that this pool of exceptional competence can be maintained.

To fight cancer, we want to increase our role in nuclear medicine. In addition to just the production of medical radioisotopes, SCK CEN is evolving into a full-fledged pharmaceutical player, in pre-clinical research as well as pilot production of new radiopharmaceuticals for cancer therapies, including its own cancer research lines.

We are constantly exploring. And have been since 1952. Driven by our passion for nuclear technology and empowered by our unique infrastructure. SCK CEN explores the limits of the possible. In this way, we continuously expand our knowledge in various nuclear fields. But no matter how many directions we explore, we always have the same goal in mind: developing innovative nuclear applications for a better world. Why? Because we are convinced that we can make a gigantic difference with one of the smallest elements on Earth – the atom. Both now and in the future. For people and nature.

For more information, please visit www.sckcen.be

Press releases

19/06/2025

PanTera secures two key permits for Actinium-225 Production Facility in MolTwo key permits required to initiate construction of its state-of-the-art Actinium-225 (Ac-225) Production Center (APC) in Mol, Belgium have been granted to PanTera. The environmental permit was granted by the Province of Antwerp, and the nuclear permit by the Federal Agency for Nuclear Control (FANC/AFCN), the two permits mark a critical step forward in PanTera’s mission to secure a global supply of Ac-225 for targeted alpha therapy in cancer treatment.

12/06/2025

PanTera produces and supplies first Actinium-225 extracted from Thorium-229 in BelgiumIn June 2025, PanTera has successfully extracted and supplied Actinium-225 (Ac-225) from its Thorium-229 (Th-229) generator, installed at its production facility in Belgium. This achievement marks the first delivery of Ac-225 under PanTera’s "Early Supply" program, powered by Th-229 material provided by TerraPower Isotopes.

Read all press releases